title: Pituitary-testicular axis in men with beta-thalassaemia major.
abstract: Delayed puberty and hypogonadism are frequently observed in patients with homozygous beta-thalassaemia. We evaluated the pituitary-testicular axis in 30 thalassaemic men, aged from 17 to 35 years who were regularly transfused and underwent chelation therapy, while emphasis was given to pituitary reserves of gonadotrophins and the correlation of hormones with serum ferritin (SF). The investigation included endocrinological examination, evaluation of serum basal levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), free testosterone and gonadotrophin-releasing hormone (GnRH) test and also spermiograms. According to the results, patients were divided into three groups: group A, which included 18 eugonadal patients with moderately elevated SF, group B which included six patients who had hypogonadotrophic hypogonadism and excessive elevation of SF, and group C, which included six patients characterized as intermediate, with regard to sexual maturation and SF levels. In conclusion, beta-thalassaemia major leads to variable pituitary iron overload and thus hypophyseal damage. This endocrine disturbance is becoming less frequent nowadays with early and intensive chelation therapy.
authors.affiliation: 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, 'Hippocration' General Hospital, Greece.
authors.forename: J
authors.initials: J
authors.lastname: Papadimas
authors.forename: E
authors.initials: E
authors.lastname: Mandala
authors.forename: G
authors.initials: G
authors.lastname: Pados
authors.forename: B
authors.initials: B
authors.lastname: Kokkas
authors.forename: G
authors.initials: G
authors.lastname: Georgiadis
authors.forename: B
authors.initials: B
authors.lastname: Tarlatzis
authors.forename: J
authors.initials: J
authors.lastname: Bontis
authors.forename: Z
authors.initials: Z
authors.lastname: Sinakos
authors.forename: S
authors.initials: S
authors.lastname: Mantalenakis
mesh_terms: D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004338:Drug Combinations; D005293:Ferritins / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000209:etiology; D008297:Male; D008596:Menotropins / Q000627:therapeutic use; D010902:Pituitary Gland / Q000503:physiopathology*; D011628:Puberty, Delayed / Q000209:etiology; D013094:Spermatozoa / Q000187:drug effects / Q000502:physiology; D013737:Testis / Q000503:physiopathology*; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D005293:Ferritins